Brought to you by 
Elan licenses Scherer's oral version of Parkinson's drug
13 Jul 1999
Executive Summary
Elan subsidiary Athena Neurosciences licensed exclusive rights for N. America, the UK, Ireland, and certain other countries to market a novel formulation of selegiline that uses the Zydis technology of RP Scherer's (drug delivery) DDS unit.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Elan licenses Scherer's oral version of Parkinson's drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice